Obesity Clinical Trial
— PEP-2Official title:
Effects of an Exercise Program Combined or Not With Nutritional intErvention on Total Fat, Epicardial Fat and Metabolic Profile of Obese and Overweight Adults With tyPe 2 Diabetes (The PEP-2 Study)
Inactivity and excess energy consumption are leading causes of obesity and type 2 diabetes which are associated with increased cardio-metabolic risk. In order to reduce the cardiovascular risk associated with type 2 diabetes, the Canadian Diabetes Association guidelines (2008) recommends weight loss through caloric restriction and structured physical activity. However, the comparative effects of different methods to obtain caloric deficit for weight loss remains to be elucidated. The main objective of this study is to assess the impact of two strategies of caloric deficit: diet alone or diet and exercise on total fat mass, epicardial fat and cardiovascular risk factors in overweight and obese adults with type 2 diabetes and at high risk of cardiovascular disease.
| Status | Completed |
| Enrollment | 90 |
| Est. completion date | April 2016 |
| Est. primary completion date | April 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 30 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Body mass index (BMI) 27-40 kg/m2 - Type 2 diabetes diagnosed since at least 3 months - High risk of cardiovascular disease : Framingham global cardiovascular risk score for 10 years > 15% or 2 or more of the following risk factors: age > 50years, dyslipidemia or treatment, high blood pressure or treatment, pathologic microalbuminuria or established proteinuria, currently smoking, family history of early cardiovascular disease (< 60 years), inactivity or high waist circumference according to IDF criteria - HbA1c : 6.0-10.0% - Stable weight for last 3 months (±3kg) reported or documented - Stable treatment for diabetes. 4 weeks: blood pressure and dyslipidemia medications. 3 months: glitazones and weight loss drugs the treatment that will be maintained at the same dose during the study; insulin will have been introduced since 4 months at least and previous month dose should be stable defined as a 10% variation or less of total daily units. Exclusion Criteria: - Pregnancy, breastfeeding - Type 1 diabetes - Secondary diabetes (e.g cystic fibrosis, steroid induced, etc.) - Recurrent, hypoglycemia without precursor signs or severe hypoglycemia occurred = 2 times for last 12 months - Renal failure , creatinine clearance < 40 ml/min (MDRD) - Severe retinopathy or neuropathy that can contra-indicate exercise or expose patient to high risk of complications (e.g wound) - NYHA classification class III or IV of cardiac insufficiency - Established coronaropathy - Non stable ventricular or supra-ventricular arrythmia - Severe limb atherosclerosis or previous amputation - Recent (< 12 months) diagnosis of cancer excepted thyroid and skin - Major mental disease - Drugs with established effects on weigh such as megace® |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Canada | Institut de recherches cliniques de Montréal (IRCM) | Montreal | Quebec |
| Lead Sponsor | Collaborator |
|---|---|
| Institut de Recherches Cliniques de Montreal |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Total fat mass | Total fat mass (kg) assessed by Dual X-Ray absoptiometry (DXA) | month 4 | No |
| Secondary | Diabetes control | A1c and fasting plasma glucose | month 4 | No |
| Secondary | Epicardial fat | Epicardial fat thickness measured by simplified cardiac echography | month 4 | No |
| Secondary | Body composition | Body composition : trunkal fat mass, apendicular fat mass, lean body mass and estimated visceral fat mass determined by DXA | month 4 | No |
| Secondary | Energy consumption | Energy consumption : as measured by total calories consumed using a three non consecutive days food journal. The three days should include one week-end day. | month 4 | No |
| Secondary | Resting metabolic rate | Resting metabolic rate determined by indirect calorimetry. | month 4 | No |
| Secondary | Total energy expenditure | Total energy expenditure estimated from 7 days accelerometer data (Senwear Armband accelerometer). | month 2,3,4 | No |
| Secondary | Physical activity energy expenditure | Physical activity energy expenditure estimated from 7 days accelerometer data (Senwear Armband accelerometer). | month 2,3,4 | No |
| Secondary | Muscle strength | upper and lower body strength using 1-RM technique | month 4 | No |
| Secondary | Cardiorespiratory fitness | Participants will perform a graded exercise test on a cycle ergometer to voluntary exhaustion. Peak oxygen consumption (VO2peak) will be considered to be the highest value obtained during the test. | month 4 | No |
| Secondary | Lipid profile | Total cholesterol, LDL-Cholesterol, HDL-cholesterol (HDL-C), Triglycerides, Apolipoprotein B, ratios TG/HDL-C and Total cholesterol/HDL-C will be determined with fasting veinous blood sample | month 4 | No |
| Secondary | Biochemical hepatic steatosis score | month 4 | No | |
| Secondary | Blood pressure | systolic and diastolic blood pressure | month 4 | No |
| Secondary | Hormonal profile | month 4 | No | |
| Secondary | Inflammatory profile | month 4 | No | |
| Secondary | Psychosocial profile | questionnaire addressing : body esteem, self-esteem, stress, dietary restraint, disinhibition, hunger, quality of life, self-efficacy,perceived benefits, perceived risks | month 4 | No |
| Secondary | Diabetes self-care | Summary of diabetes care activities (SDCA) questionnaire | month 4 | No |
| Secondary | visceral fat thickness | month 4 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |